Document Detail

Intensified therapy in acute lymphoblastic and acute undifferentiated leukemia in adults.
MedLine Citation:
PMID:  6375764     Owner:  NLM     Status:  MEDLINE    
One hundred seventy adult patients with acute lymphoblastic leukemia (ALL) or acute undifferentiated leukemia (AUL) were entered into a prospective multicenter therapy trial at 25 hospitals. The aim of the trial was to improve remission duration by using a modified form of an intensified induction regimen that was successful in childhood ALL, to define immunologic subtypes of ALL by use of cell-surface markers, and to extract other possible prognostic factors. The overall complete remission rate was 77.8%. The median overall survival time was 26 months, being 4 months for nonresponders and 32 months for responders. The median remission duration for the 126 patients with complete remission was 20 months. Prognostically favorable factors for remission duration were response to chemotherapy within 4 weeks, age less than 35 years, a low initial leukocyte count, and the immunologic subtypes c-ALL with early response to therapy and T-ALL, where 61% and 58%, respectively, are still in complete remission at 3 years. An adverse influence on remission duration was observed for the subtype null-ALL, with a median survival of 13 months, and for patients with a delayed response to induction therapy, independent of phenotype.
D Hoelzer; E Thiel; H Löffler; H Bodenstein; L Plaumann; T Büchner; D Urbanitz; P Koch; H Heimpel; R Engelhardt
Related Documents :
9711884 - Methylprednisolone pulse therapy in two clinical types of crescentic glomerulonephritis.
10942364 - Definition of relapse risk and role of nonanthracycline drugs for consolidation in pati...
18946754 - Intensive chemotherapy improved treatment outcome for chinese children and adolescents ...
281594 - Acute promyelocytic leukemia presenting as a pelvic mass.
23733674 - Efficacy of nimotuzumab combined with docetaxel-cisplatin-fluorouracil regimen in treat...
22006744 - Controversies in the management of advanced non-small cell lung cancer: maintenance the...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Blood     Volume:  64     ISSN:  0006-4971     ISO Abbreviation:  Blood     Publication Date:  1984 Jul 
Date Detail:
Created Date:  1984-07-30     Completed Date:  1984-07-30     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7603509     Medline TA:  Blood     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  38-47     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute Disease
Age Factors
Antineoplastic Agents / adverse effects,  therapeutic use
B-Lymphocytes / immunology
Clinical Trials as Topic
Leukemia / drug therapy*,  mortality
Leukemia, Lymphoid / drug therapy*
Leukocyte Count
Middle Aged
Prospective Studies
Receptors, Antigen, B-Cell / immunology
Statistics as Topic
T-Lymphocytes / immunology
Reg. No./Substance:
0/Antineoplastic Agents; 0/Receptors, Antigen, B-Cell

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Human large granular lymphocytes and their relationship to natural killer cell activity in various d...
Next Document:  Coenzyme function of cobalamin analogues from calf kidney.